Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.

  • Posted by: Biocon Biologics

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Bengaluru, India; April 28, 2021: 

Biocon Ltd (BSE code: 532523, NSE: BIOCON) is pleased to announce that its Executive Chairperson Kiran Mazumdar-Shaw has been appointed to the Board of Trustees of Memorial Sloan Kettering Cancer Center (MSK), a world leader in cancer treatment and research, based in New York, U.S. She is among the 52 members on the board and will serve for a term of three years w.e.f. April 14, 2021.

Ms. Mazumdar-Shaw is the first woman of Indian nationality to be appointed for this prestigious role.

Memorial Sloan Kettering is ranked as one of the top two hospitals for cancer care in the U.S. for more than 30 years and among the nation’s top pediatric hospitals for cancer care, according to US News & World Report. Memorial Sloan Kettering maintains one of the world’s most dynamic programs of cancer research, with more than 120 research laboratories that are focused on better understanding every type of the disease.

Author: Biocon Biologics
Share